SureTrader SureTrader
Home > Boards > US Listed > Medical - Drugs > Momenta Pharmaceuticals, Inc. (MNTA)

MOMENTA PHARMACEUTICALS, INC. v. AMPHASTAR PHARMACEUTICALS, INC.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
floblu14 Member Profile
Member Level 
Followed By 18
Posts 2,560
Boards Moderated 0
Alias Born 07/20/06
160x600 placeholder
Initial Statement of Beneficial Ownership (3) "Edgar (US Regulatory)" - 12/7/2016 9:51:59 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 11/29/2016 9:09:00 AM
Momenta Pharmaceuticals Announces Positive Top-Line Phase 3 Results for M923, a Proposed HUMIRA® (adalimumab) Biosimilar "GlobeNewswire Inc." - 11/29/2016 8:00:00 AM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 11/23/2016 10:54:01 AM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 11/23/2016 10:47:45 AM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 11/23/2016 10:42:27 AM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 11/23/2016 10:37:44 AM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 11/23/2016 10:33:52 AM
Momenta Pharmaceuticals Announces Publication on the Design of M230, a Novel Autoimmune Disease Drug Candidate, in Science Tr... "GlobeNewswire Inc." - 11/17/2016 8:00:00 AM
Quarterly Report (10-q) "Edgar (US Regulatory)" - 11/4/2016 4:01:34 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 11/2/2016 8:40:57 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 11/2/2016 8:37:57 AM
Momenta Pharmaceuticals Appoints Scott M. Storer as Senior Vice President and Chief Financial Officer "GlobeNewswire Inc." - 11/2/2016 8:00:00 AM
Momenta and Mylan Initiate Phase 1 Clinical Trial for M834, a Proposed Biosimilar of ORENCIA® (abatacept) "PR Newswire (US)" - 11/2/2016 8:00:00 AM
Momenta Pharmaceuticals to Webcast at Two Upcoming Investor Conferences "GlobeNewswire Inc." - 10/31/2016 8:00:00 AM
Momenta Pharmaceuticals Announces Date for Third Quarter 2016 Financial Results Conference Call and Webcast "GlobeNewswire Inc." - 10/20/2016 8:00:00 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 10/19/2016 8:38:36 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 9/27/2016 8:36:57 AM
Momenta Pharmaceuticals to Regain Global Development and Commercialization Rights to M923, a Proposed Biosimilar of HUMIRA® ... "GlobeNewswire Inc." - 9/27/2016 8:00:00 AM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 9/26/2016 3:49:57 PM
Amended Statement of Beneficial Ownership (3/a) "Edgar (US Regulatory)" - 9/26/2016 3:39:49 PM
Initial Statement of Beneficial Ownership (3) "Edgar (US Regulatory)" - 9/23/2016 12:07:48 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 9/23/2016 8:12:45 AM
Momenta Pharmaceuticals Appoints Corey N. Fishman to Board of Directors "GlobeNewswire Inc." - 9/23/2016 8:00:00 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 9/19/2016 4:14:26 PM
floblu14 Member Level  Wednesday, 12/07/11 09:36:20 AM
Re: None
Post # of 16222 
MOMENTA PHARMACEUTICALS, INC. v. AMPHASTAR PHARMACEUTICALS, INC.

MOMENTA PHARMACEUTICALS, INC., Plaintiff-Appellee, and
SANDOZ, INC., Plaintiff-Appellee,
v.
AMPHASTAR PHARMACEUTICALS, INC., INTERNATIONAL MEDICATION SYSTEMS, LTD., WATSON PHARMACEUTICALS, INC. and WATSON PHARMA, INC., Defendants-Appellants.

Nos. 2012-1062, 2012-xxxx, 2012-xxxx

United States Court of Appeals, Federal Circuit.


December 6, 2011.


This order is nonprecedential

ORDER

Upon consideration of the November 17, 2011 order expediting briefing on the merits of this appeal, the motions to consolidate this appeal with forthcoming appeals, the motion for leave to file a corrected opening brief, the motion for leave to file public and confidential versions of its reply in support of its motion to stay the injunction, and the motions to amend the official caption to add Watson Pharma, Inc.,

IT IS ORDERED THAT:
(1) Oral argument for the merits of the appeal is scheduled to be held at 10 a.m., January 24, 2012, in Courtroom 201. The parties shall notify the clerk in writing of the name of the counsel who will present oral argument no later than January 9, 2012.
(2) The motions to consolidate will be granted and the official caption will be amended to add the appeal numbers from the district court's November 23, 2011 order denying their motion to dissolve the injunction and the district court's December 2, 2011 order denying their emergency motion for relief from the injunction, when those new appeals are docketed by this court.
(3) The motions to reform the caption are granted. Watson Pharma, Inc. is added to the caption. The revised official caption is reflected above.

http://www.leagle.com/xmlResult.aspx?xmldoc=In%20FCO%2020111206163.xml&docbase=CSLWAR3-2007-CURR


SureTrader
Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist